HNF4A and neoplasm: To test this hypothesis, AAI‐treated Arid1aLKO mice were given either vehicle or ICG‐001 (Figure7A), a small molecule that specifically disrupts β‐catenin/CBP interaction and thereby inhibits β‐catenin/TCF target gene transcription.[53] After two months of treatment, ICG‐001 significantly reduced liver/body weight ratio, tumor incidence, and the number of large tumor nodules (> 3 mm) in AAI‐treated Arid1aLKO mice compared to vehicle‐treated controls (Figure 7B,C).